肝动脉灌注化疗的现状与前景

摘要/Abstract

中图分类号:

R735.7

石明, 何敏柯, 陈敏山. 肝动脉灌注化疗的现状与前景[J]. 外科理论与实践, 2020, 25(01): 10-14.

SHI Ming, HE Minke, CHEN Minshan. Current status and future perspective of hepatic artery infusion chemotherapy[J]. Journal of Surgery Concepts & Practice, 2020, 25(01): 10-14.

参考文献30

[1]	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2017, 3(4):524-548. doi:10.1001/jamaoncol.2016.5688pmid:27918777
[2]	Benson AB, D'Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019[J]. J Natl Compr Canc Netw, 2019, 17(4):302-310.
[3]	He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorinvs. sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7):953-960.
[4]	Song DS, Song MJ, Bae SH, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Gastroenterol, 2015, 50(4):445-454.
[5]	Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenibvs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2018, 82(3):469-478.
[6]	Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorinvs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):60-69.
[7]	Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based Clinical Practice Guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan[J]. Liver Cancer, 2014, 3(3-4):458-468.
[8]	Hiramine Y, Uto H, Imamura Y, et al. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study[J]. Exp Ther Med, 2011, 2(3):433-441.
[9]	Jeong SW, Jang JY, Lee JE, et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma[J]. Asia Pac J Clin Oncol, 2012, 8(2):164-171.
[10]	Fukubayashi K, Tanaka M, Izumi K, et al. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method[J]. Cancer Medicine, 2015, 4(8):1214-1223. doi:10.1002/cam4.476pmid:26044168
[11]	Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy[J]. Liver Cancer, 2015, 4(3):188-199.
[12]	He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1):83.
[13]	Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis[J]. Cancer, 2000, 88(9):1986-1991. pmid:10813709
[14]	Kawaoka T, Aikata H, Kobayashi T, et al. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma[J]. Hepatol Res, 2018, 48(13):1118-1130.
[15]	Ikeda M, Okusaka T, Furuse J, et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2013, 72(2):463-470.
[16]	Nouso K, Miyahara K, Uchida D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013, 109(7):1904-1907.
[17]	Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leuco-vorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28):3501-3508.
[18]	Morito M, Masato S, Yuh S, et al. 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase Ⅱ study[J]. Hepatol Res, 2012, 42(2):150-165. doi:10.1111/j.1872-034X.2011.00905.xpmid:22044786
[19]	Zhuang BW, Li W, Xie XH, et al. Sorafenib versus he-patic arterial infusion chemotherapy for advanced hepato-cellular carcinoma: a systematic review and meta-analysis[J]. Jpn J Clin Oncol, 2019, 49(9):845-855.
[20]	Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: rando-mized phase Ⅱ trial[J]. Ann Oncol, 2016, 27(11):2090-2096. pmid:27573564
[21]	Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):424-432.
[22]	He MK, Zou RH, Li QJ, et al. Phase Ⅱ Study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis[J]. Cardiovasc Intervent Radiol, 2018, 41(5):734-743.
[23]	Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(11):3308-3315. doi:10.1245/s10434-018-6653-9pmid:30083834
[24]	Kodama K, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced he-patocellular carcinoma patients with major portal vein tumor thrombosis[J]. Oncology, 2018, 94(4):215-222.
[25]	Hamaoka M, Kobayashi T, Kuroda S, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study[J]. Int J Surg, 2017, 44:223-228.
[26]	Hatooka M, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J]. Anticancer Res, 2016, 36(7):3523-3529.
[27]	Ikeda M, Mitsunaga S, Shimizu S, et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J]. J Gastroenterol, 2014, 49(5):932-940.
[28]	Moriya K, Namisaki T, Sato S, et al. Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma[J]. J Gastrointest Oncol, 2018, 9(4):741-749. doi:10.21037/jgo.2018.05.13pmid:30151271
[29]	Shiozawa K, Watanabe M, Ikehara T, et al. Efficacy of sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J]. Gan To Kagaku Ryoho, 2015, 42(8):953-956.
[30]	Moran A, Ramos LF, Picado O, et al. Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapyvs. resection alone. A systematic review and meta-analysis[J]. J Surg Oncol, 2019, 119(4):455-463.

肝动脉灌注化疗的现状与前景

Current status and future perspective of hepatic artery infusion chemotherapy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献30

相关文章15

编辑推荐

Metrics

本文评价

[1]	叶枫, 龚笑勇, 任家俊, 蔡强, 陈胜.ERCP在原发性肝癌围术期胆道并发症诊治中的应用[J]. 外科理论与实践, 2023, 28(04): 355-360.
[2]	孙祺, 黄文博, 何炳良, 刘畅, 徐宇航, 赵伟.预防性腹腔热灌注化疗对局部进展期胃癌根治术后病人预后改善的有效性研究[J]. 外科理论与实践, 2023, 28(04): 366-370.
[3]	Chang Jessica, 陈旭晓, 陈拥军.脾脏在肝癌合并肝硬化中的临床价值[J]. 外科理论与实践, 2023, 28(04): 394-398.
[4]	李相成, 陈妍安澜, 李长贤.肝门部胆管癌根治性切除术中的血管重建技术[J]. 外科理论与实践, 2023, 28(02): 104-109.
[5]	张辉, 龚玲, 郭茜, 罗艳.肝癌全身麻醉射频消融术后应用舒更葡糖钠逆转神经肌肉阻滞的回顾性研究[J]. 外科理论与实践, 2023, 28(01): 72-76.
[6]	陈聪燕综述, 王俊青, 陈拥军审校.肠道菌群与肝癌的发病机制[J]. 外科理论与实践, 2022, 27(03): 256-260.
[7]	汤钊猷.中华哲学思维对肝癌治疗的启迪[J]. 外科理论与实践, 2022, 27(02): 93-94.
[8]	朱鹏, 廖威, 张必翔, 陈孝平.机器人肝癌肝切除应用现状与前景[J]. 外科理论与实践, 2022, 27(02): 95-99.
[9]	曹君, 陈亚进.腹腔镜解剖性肝切除治疗肝癌的规范与思考[J]. 外科理论与实践, 2022, 27(02): 123-127.
[10]	任家俊, 陈拥军.肝脾联合切除治疗原发性肝癌合并门静脉高压及脾功能亢进[J]. 外科理论与实践, 2022, 27(02): 139-144.
[11]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜.肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[12]	吴冬梅, 吴丽莉, 陈佳, 刘坤.淋巴上皮样肝细胞肝癌一例报告附文献复习[J]. 诊断学理论与实践, 2021, 20(05): 498-501.
[13]	苏长青.从基础研究到临床转化应用谈肝癌的诊治进展[J]. 诊断学理论与实践, 2021, 20(05): 427-433.
[14]	司安锋, 雷正清, 杨平华, 江涛, 王轩, 程张军.巨块型肝内胆管癌术后经肝动脉化疗栓塞的有效性[J]. 外科理论与实践, 2021, 26(02): 138-143.
[15]	朱正纲.预防与治疗胃癌腹膜转移的若干关键问题[J]. 外科理论与实践, 2021, 26(01): 1-6.